Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease

Archives of Dermatology

Volumn 144, Issue 8, 2008, Pages 1081-1082

  Guenova, Emmanuella ^a   Weber, Hans Oliver ^b   Voykov, Bogmil ^b   Metzler, Gisela ^b   Mitev, Vanyo ^b   Berneburg, Mark ^b   Hoetzenecker, Wolfram ^b   Röcken, Martin ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; ORAL ANTIDIABETIC AGENT; PROSTAGLANDIN E1; SUNITINIB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ANAMNESIS; ANEMIA; BLOOD RHEOLOGY; CASE REPORT; DIABETIC ANGIOPATHY; DRUG WITHDRAWAL; DYSGEUSIA; FOOT DISEASE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETTER; LIMB AMPUTATION; MALE; METASTASIS; NECROTIC FOOT SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; WOUND CARE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DIABETIC ANGIOPATHIES; DRUG ERUPTIONS; FOOT; FOOT DISEASES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; PARESTHESIA; PYRROLES; SKIN;

EID: 49949094355     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.8.1081     Document Type: Letter

References (9)

1. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107-113.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
3. Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol. 2008;144(1):123-125.
4. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-234.
5. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol. 2006;24(36):5786-5788.
6. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-2524.
7. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500.
8. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008;158(3):592-596.
9. Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25(6):599-602.